华海药业子公司HB0025注射液启动III期临床试验

Core Viewpoint - Huahai Pharmaceutical (600521.SH) announced the initiation of Phase III clinical trials for HB0025, an innovative anti-PD-L1/VEGF bispecific fusion protein targeting squamous and non-squamous non-small cell lung cancer [1] Group 1: Clinical Development - The company’s subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd. (referred to as "Huatai"), has completed discussions with the National Medical Products Administration (NMPA) regarding the transition from Phase II to Phase III clinical trials for HB0025 [1] - HB0025 is designed to target both the PD-L1 immune evasion pathway and the VEGF angiogenesis pathway, providing a dual mechanism of action for anti-tumor effects [1] Group 2: Drug Mechanism - The drug achieves high-affinity binding to two targets, which helps in the coordinated regulation of the tumor immune microenvironment and angiogenesis [1] - The dual mechanism of action includes both immune enhancement and anti-angiogenesis properties, positioning HB0025 as a promising candidate in cancer therapy [1]